Amneal Pharmaceuticals (AMRX) Institutional Ownership

31.82% of Amneal Pharmaceuticals' stock is owned by institutional investors. Learn more on AMRX's institutional investor holdings.

Of the 249 institutional investors that purchased Amneal Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Assenagon Asset Management S.A. ($3.73M), Rubric Capital Management LP ($2.78M), Allspring Global Investments Holdings LLC ($2.51M), Nuveen LLC ($2.34M), Nantahala Capital Management LLC ($1.75M), Acadian Asset Management LLC ($1.66M), and BlackBarn Capital Partners LP ($1.62M).

Institutional investors have bought a total of 31,772,797 shares in the last 24 months. This purchase volume represents approximately $348.08M in transactions.

Of the 83 institutional investors that sold Amneal Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Nantahala Capital Management LLC ($1.92M), Millennium Management LLC ($1.71M), Royal Bank of Canada ($1.53M), Rubric Capital Management LP ($1.30M), JPMorgan Chase & Co. ($1.23M), Invesco Ltd. ($1.10M), and Arrowstreet Capital Limited Partnership ($1.06M).

Institutional investors have sold a total of 16,253,901 shares in the last 24 months. This volume of shares sold represents approximately $181.13M in transactions.